drugset
drugset / Trial / NCT02284906

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

NCT02284906 ↗

Phase 3 Terminated 40 enrolled Takeda
Non-randomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40\_301 study \[NCT01931566\] with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).

Timeline

Start
2015-02-12
Primary completion
2018-01-31
Completion
2018-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 0.8 mg Oral

Indications

Alzheimer disease